OBJECTIVE: To evaluate the association of patient- and clinician-level factors and receipt of prescription medication for menopause-related symptoms in a large academic health care system. METHODS: We conducted a retrospective cohort study of women aged 40-55 years seeking care for menopause-related symptoms in any outpatient encounter with family medicine, internal medicine, endocrinology, and OB/Gyn from 2016 to 2023. Prescriptions associated with menopause-related ICD-10 diagnoses were extracted. Bivariate and multivariable logistic regression were used to evaluate the association of patient- and clinician-level characteristics and receipt of prescription treatment. RESULTS: We identified 5,491 women with an outpatient encounter with an associated ICD-10 code for menopause-related symptoms. Relative to White women, Black women were less likely to receive any prescription treatment for menopause-related symptoms (OR: 0.79, 95% CI: 0.67-0.95), including systemic estrogen (OR: 0.64, 95% CI: 0.47-0.87); however, were more likely to receive SSRIs (OR: 1.49, 95% CI: 1.04-2.14). Relative to patients seeking care within OB/Gyn settings, patients were less likely to be prescribed any treatment by internal medicine (OR: 0.45, 95% CI: 0.36-0.56), family medicine (OR: 0.52, 95% CI: 0.14-0.40), and endocrinology clinicians (OR: 0.23, 95% CI: 0.14-0.40). CONCLUSION: Our study demonstrates differential prescribing patterns for menopause-related symptoms with respect to race, insurance status, and clinician specialty. Our results underscore the need for equitable care for women experiencing menopause symptoms.
No takes yet. Share an insight, caveat, or question.
Cochrane et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: